Table 3.
In vitro activity of antimicrobial agents against Gram-negative ESKAPE pathogens isolated from patients in ICUs and non-ICU wards.
| Source/organism/patient location (n) | % Susceptible |
|||||||
|---|---|---|---|---|---|---|---|---|
| AMK | FEP | CAZ | CRO | ETP | IPM | LVX | TZP | |
| Intra-abdominal infections | ||||||||
| K. pneumonia | ||||||||
| ICU (262) | 90.1 | 49.6 | 53.1 | 50.0 | 76.7 | 80.5 | 65.3 | 56.9 |
| Non-ICU (712) | 93.0 | 58.0 | 59.0 | 55.8 | 83.7 | 88.5 | 67.6 | 68.0 |
| K. pneumoniae, ESBL-positive | ||||||||
| ICU (117) | 84.6 | 4.3 | 12.0 | 4.3 | 63.3 | 71.8 | 43.6 | 29.9 |
| Non-ICU (292) | 88.0 | 6.9 | 10.6 | 3.1 | 70.6 | 82.2 | 41.1 | 38.4 |
| K. pneumoniae, ESBL-negative | ||||||||
| ICU (145) | 94.5 | 86.2 | 86.2 | 86.9 | 87.6 | 87.6 | 82.8 | 78.6 |
| Non-ICU (420) | 96.4 | 93.6 | 92.6 | 92.4 | 92.9 | 92.9 | 86.0 | 88.6 |
| Enterobacter spp. | ||||||||
| ICU (112) | 96.4 | 69.6 | 53.6 | 48.2 | 72.3 | 92.0 | 87.5 | 67.0 |
| Non-ICU (321) | 97.8 | 76.6 | 69.2 | 63.6 | 87.5 | 93.2 | 86.9 | 80.4 |
| P. aeruginosa | ||||||||
| ICU (142) | 81.0 | 71.1 | 73.9 | NA | NA | 62.7 | 72.5 | 69.7 |
| Non-ICU (428) | 86.7 | 79.4 | 79.4 | NA | NA | 75.5 | 76.2 | 80.4 |
| A. baumannii | ||||||||
| ICU (48) | 33.3 | 14.6 | 16.7 | 6.3 | NA | 14.6 | 8.3 | 10.4 |
| Non-ICU (88) | 29.6 | 21.6 | 23.9 | 13.6 | NA | 23.9 | 19.3 | 20.5 |
| Urinary tract infections | ||||||||
| K. pneumonia | ||||||||
| ICU (153) | 91.5 | 41.2 | 43.1 | 38.6 | 70.6 | 76.5 | 52.9 | 53.6 |
| Non-ICU (444) | 92.6 | 52.5 | 53.8 | 48.7 | 77.3 | 83.1 | 58.8 | 64.2 |
| K. pneumoniae, ESBL-positive | ||||||||
| ICU (81) | 87.7 | 4.9 | 8.6 | 1.2 | 60.5 | 72.8 | 33.3 | 34.6 |
| Non-ICU (197) | 86.8 | 8.1 | 12.2 | 2.0 | 63.5 | 77.2 | 35.0 | 38.6 |
| K. pneumoniae, ESBL-negative | ||||||||
| ICU (72) | 95.8 | 81.9 | 81.9 | 80.6 | 81.9 | 80.6 | 75.0 | 75.0 |
| Non-ICU (247) | 97.2 | 87.9 | 87.0 | 85.8 | 88.3 | 87.9 | 77.7 | 84.6 |
| Enterobacter spp. | ||||||||
| ICU (49) | 95.9 | 65.3 | 53.1 | 49.0 | 75.5 | 89.8 | 81.6 | 65.3 |
| Non-ICU (116) | 90.5 | 69.8 | 62.9 | 56.9 | 81.0 | 84.5 | 74.1 | 75.0 |
| P. aeruginosa | ||||||||
| ICU (54) | 79.6 | 70.4 | 64.8 | NA | NA | 66.7 | 66.7 | 70.4 |
| Non-ICU (111) | 73.0 | 56.8 | 61.3 | NA | NA | 56.8 | 49.6 | 55.0 |
| A. baumannii | ||||||||
| ICU (18) | 22.2 | 5.6 | 16.7 | 5.6 | NA | 16.7 | 5.6 | 16.7 |
| Non-ICU (25) | 12.0 | 16.0 | 20.0 | 16.0 | NA | 20.0 | 16.0 | 20.0 |
AMK, amikacin; FEP, cefepime; CAZ, ceftazidime; CRO, ceftriaxone; ETP, ertapenem; IPM, imipenem; LVX, levofloxacin; TZP, piperacillin-tazobactam; NA, not applicable (CLSI breakpoints are not available for ceftriaxone and ertapenem tested against P. aeruginosa and for ertapenem tested against A. baumannii).